Please login to the form below

Not currently logged in

Novartis' Rydapt

This page shows the latest Novartis' Rydapt news and features for those working in and with pharma, biotech and healthcare.

NICE recommends NovartisRydapt for advanced SM treatment

NICE recommends Novartis’ Rydapt for advanced SM treatment

The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Rydapt (midostaurin) for the treatment of aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasms or mast cell

Latest news

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Subscribe to our email news alerts


Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...